The most powerful
biomarker discovery platform
GEMMAai™
GEnoMic Marker Analyzer
AI-Powered platform for matching patients with right treatment
GEMMAai for clinical trial enrolment – available *
GEMMAai for companion diagnostics development – available *
GEMMAai for patients coming soon – pipeline *
TUMOR
TYPE
TUMOR GENOMES
TARGETED THERAPY
DISCOVERY
PROTOTYPE ASSAY
ANALITYCAL VALIDATION
CLINICAL VALIDATION
REGULATORY APPROVAL
UPCOMING
MILESTONES
BREAST
2152
CDK4/6i
Ant-HER2
PARPi
mTORi
PIK3i
2 analytically validated diagnostic tools in Q1 2021
OVARIAN
512
Carboplatin / PARPi
FDA breakthrough device submission Q2 2021
FASETM
GENOMIC FEATURE DATABASE
YOUR inhibitor
Discovery and validation
AI-POWERED
STRATIFICATION DIAGNOSTIC TOOL
* For Research Use Only. Not for use in diagnostic procedures.
TUMOR TYPE: OVARIAN
WGS DATA
512
TARGETTED THERAPY
UPCOMING MILESTONES
FDA breakthrough device in Q3 2021
TUMOR TYPE: BREAST
WGS DATA
2152
TARGETTED THERAPY
UPCOMING MILESTONES
2 analytically validated diagnostic tools in Q1 2021
TUMOR TYPE: LUNG
WGS DATA
1852
TARGETTED THERAPY
UPCOMING MILESTONES
2 prototype assays in Q3 2021
FUSETM
WGS DATA
GENOMIC FEATURE DATABASE
TARGETTED THERAPY
YOUR inhibitor
DISCOVERY AND VALIDATION
AI-POWERED STRATIFICATION DIAGNOSTIC TOOL
News
IV Krajowa Naukowo-Szkoleniowa Konferencja Biobanków Polskich
BiO€QUITY Europe on 17-19 May 2021
Certificate of Approval ISO 9001:2015
The success of Polish scientists. Research on COVID-19 has been recognized as one of the most remarkable discoveries in 2020 by Nature
Our publications
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers

The First Report of Biallelic Missense Mutations in the SFRP4 Gene Causing Pyle Disease in Two Siblings

A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection

Masz pytania lub wątpliwości?